focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: RWS and James Cropper sink on profit warnings

Wed, 23rd Mar 2022 11:21

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

4D Pharma PLC, up 37% at 61.45 pence, 12-month range 24.46p-135.00p. The pharmaceutical company says its therapeutic treatment MRx0518, in combination Merck's Keytruda, met its primary efficacy endpoint ahead of trial enrolment completion.

----------

AIM - LOSERS

----------

RWS Holdings PLC, down 27% at 342.00p, 12-month range 326.00p-701.00p. The technology-enabled language services provider warns its annual performance is set to be at the lower end of expectations.

RWS will no longer provide services or technology to Russian-owned businesses, and also expects reduced demand for translation into Russian from non-Russian owned companies. As a result, revenue growth from the Language Services unit is set to moderate, and RWS's overall performance for the year is anticipated to be at the lower end of market expectations.

----------

James Cropper PLC, down 18% at 1,002.00p, 12-month range 1,002.00p-1,650.00p. Shares in the paper products manufacturer hit a 12-month low as it warns it will miss previous expectations for profit. For the year ending March 26, James Cropper notes 30% growth in sales, ahead of prior market expectations due to strong demand across all divisions. However, it now expects adjusted pretax profit of GBP3.5 million, a sharp rise from GBP1.1 million the year before, but below prior expectations of GBP4.9 million. This is due to the conflict between Russia and Ukraine, and the resulting jump in energy costs, which affected the Paper division the most, due to being the most energy-intensive division.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
8 Apr 2016 08:25

4D Pharma Buys Assets From Partner In Deal Worth Up To EUR6 Million (ALLISS)

Read more
31 Mar 2016 08:47

4d Pharma Annual Loss Widens On Higher Research Spending

Read more
26 Feb 2016 15:49

Good news, and some not-so-good news from 4D pharma

(ShareCast News) - 4D pharma brought some good news and some bad news to the market on Friday, over its trials of irritable bowel syndrome (IBS) treatment Blautix, and it paediatric Crohn's disease treatment Thetanix. The AIM-traded pharmaceutical company, with a focus on the development of live bio

Read more
26 Feb 2016 09:16

4D Pharma Quality Concerns Delay Thetanix Dosing, Recruits For Blautic

Read more
10 Feb 2016 15:12

4D Pharma expands research with Tuscana acquisition

(ShareCast News) - 4D Pharma expanded its research capabilities on Wednesday, acquiring university-based startup Tuscana Health Limited. The AIM traded pharmaceutical company, focused on the development of live biotherapeutics, said Tuscana - based at University College Cork - was founded to investi

Read more
10 Feb 2016 08:57

4D Pharma Acquires University Start-Up Company Tucana Health (ALLISS)

Read more
19 Jan 2016 07:51

4d Pharma Gets Good Early Results From Blautix Trials

Read more
8 Dec 2015 07:46

4d Pharma Raises GBP30.0 Million For Business Development (ALLISS)

Read more
26 Nov 2015 10:10

4D Pharma Finds Live Biotherapeutic For Breast, Lung Cancer Treatment

Read more
11 Nov 2015 11:15

4D Pharma Gets Approval For Phase 1 Study Of Crohn's Disease Drug

Read more
29 Sep 2015 12:08

4D Pharma Progresses Pipeline As It Swings To Loss In First Half

Read more
21 Aug 2015 06:49

4D Pharma Commences Dosing In Irritable Bowel Syndrome Clinical Trial

Read more
11 Aug 2015 14:15

FTSE 250 movers: Miners drag index down, Synthomer spikes higher

(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews. By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta

Read more
7 Aug 2015 06:31

4D Pharma Agrees EUR4.8 Million Collaboration With APC Microbiome

Read more
16 Jun 2015 08:33

4D Pharma posts "exciting" development results from MicroRx

Pharmaceutical company 4D Pharma said it had made significant progress in its research efforts using its proprietary platform MicroRx. The Manchester-based outfit was able to identify candidates for the treatment of severe asthma, allergic asthma and rheumatoid arthritis. The group also identified

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.